ArticleBMC infectious diseases2026
Beyond traditional tetracyclines: a real-world evaluation of effectiveness and safety of omadacycline therapy for complex bacterial infections.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOmadacycline (OMC) is an aminomethylcycline antibiotic approved in 2018 for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia in adults. This study assessed the effectiveness and safety of OMC in real-world clinical settings across the United States.
methodsWe conducted a multicenter, retrospective cohort study at 12 U.S. medical centers including adults who received OMC between October 2018 and October 2023. The primary outcome for definitive therapy was clinical cure, defined as resolution of infectious signs and symptoms without the need for alternative therapy due to concern for failure. For suppressive therapy, the primary outcome was breakthrough infection within 90 days, defined as recurrence with the same pathogen at the same site. Secondary outcomes included 30-day survival, recurrence, readmission, and adverse effects (AEs).
resultsEighty-six patients were included; median (interquartile range [IQR]) age was 63 years (46.0-66.0), 52.3% were male, and 67.4% were white. Most received outpatient therapy (84.9%). The median Charlson Comorbidity Index was 8.5. Common infections included osteomyelitis (30.2%) and skin/soft tissue infections (27.9%). OMC was used as targeted therapy in 69.8% and as suppressive therapy in 30.2%. Clinical cure was achieved in 81.7%, and 30-day survival was 95.3%. Microbiologic recurrence occurred in 10.3% and breakthrough infection in 15.4%. AEs were reported in 19.8%, predominantly gastrointestinal (88.2%).
conclusionOMC demonstrated high clinical effectiveness and tolerability across a range of infections, supporting its role in patients with resistant pathogens or limited treatment options. Further prospective studies are warranted. CLINICAL
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.